z-logo
Premium
Redox‐ and Temperature‐Controlled Drug Release from Hollow Mesoporous Silica Nanoparticles
Author(s) -
Jiao Yunfeng,
Sun Yangfei,
Chang Baisong,
Lu Daru,
Yang Wuli
Publication year - 2013
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201301060
Subject(s) - cystamine , mesoporous silica , nanoparticle , ethylene glycol , controlled release , polymer , drug delivery , materials science , mesoporous material , glutathione , copolymer , chemistry , nanotechnology , chemical engineering , combinatorial chemistry , organic chemistry , biochemistry , engineering , enzyme , catalysis
A controlled drug‐delivery system has been developed based on mesoporous silica nanoparticles that deliver anticancer drugs into cancer cells with minimized side effects. The copolymer of two oligo(ethylene glycol) macromonomers cross‐linked by the disulfide linker N , N ′‐bis(acryloyl)cystamine is used to cap hollow mesoporous silica nanoparticles (HMSNs) to form a core/shell structure. The HMSN core is applied as a drug storage unit for its high drug loading capability, whereas the polymer shell is employed as a switch owing to its redox/temperature dual responses. The release behavior in vitro of doxorubicin demonstrated that the loaded drugs could be released rapidly at higher temperature or in the presence of glutathione (GSH). Thus, the dual‐stimulus polymer shell exhibiting a volume phase transition temperature higher than 37 °C can effectively avoid drug leakage in the bloodstream owing to the swollen state of the shell. Once internalized into cells, the carriers shed the polymer shell because of cleavage of the disulfide bonds by GSH, which results in the release of the loaded drugs in cytosol. This work may prove to be a significant development in on‐demand drug release systems for cancer therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here